Concepedia

Author

Teodoro Sava

Istituti di Ricovero e Cura a Carattere ScientificoORCID

Also Known As

Camilla Sartragno, Donata Sartori, Filippo Migliorini, T Sava, T. Sava, Teodoro Sava, Tudor V. Sava

152

Publications

2K

Citations

26

H-Index

37

Concepts

All Affiliations

Istituti di Ricovero e Cura a Carattere ScientificoAzienda Ospedaliera Universitaria Integrata VeronaIstituto Oncologico VenetoUniversity of VeronaIstituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
TS

About

Teodoro Sava is an author at Istituti di Ricovero e Cura a Carattere Scientifico specializing in medicine, oncology, and urology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

17

22

899

2

Engineering

1

1

17

3

Health Sciences

1

1

83

4

Cell Biology

1

1

40

5

Immunology

1

1

70

Teodoro Sava

×

41

Publications

1.8K

Citations

24

H-Index

YearCitations

Systemic immune-inflammation index predicts the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib

Cristian Lolli, Umberto Basso, Lisa Derosa,

Oncotarget

2016

150

Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial

Andrea Necchi, Luigi Mariani, Nadia Zaffaroni,

The Lancet Oncology

2012

145

M30 Neoepitope Expression in Epithelial Cancer: Quantification of Apoptosis in Circulating Tumor Cells by CellSearch Analysis

Elisabetta Rossi, Umberto Basso, Romina Celadin,

Clinical Cancer Research

2010

128

Lymphatic and vascular embolizations are independent predictive variables of inguinal lymph node involvement in patients with squamous cell carcinoma of the penis

Vincenzo Ficarra, Filiberto Zattoni, Sergio Cosciani Cunico,

Cancer

2005

126

Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis

Sergio Bracarda, Roberto Iacovelli, Luca Boni,

Annals of Oncology

2015

105

Brain Metastases in Patients With Germ Cell Tumors: Prognostic Factors and Treatment Options—An Analysis From the Global Germ Cell Cancer Group

Darren R. Feldman, Anja Lorch, Andrew Kramar,

Journal of Clinical Oncology

2015

88

Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study

Orazio Caffo, Ugo De Giorgi, Lucia Fratino,

European Urology

2014

83

Magnitude of PD-1, PD-L1 and T Lymphocyte Expression on Tissue from Castration-Resistant Prostate Adenocarcinoma: An Exploratory Analysis

Francesco Massari, Chiara Ciccarese, Anna Caliò,

Targeted Oncology

2015

70

Dynamic changes of live/apoptotic circulating tumour cells as predictive marker of response to Sunitinib in metastatic renal cancer

Elisabetta Rossi, Matteo Fassan, Michele Aieta,

British Journal of Cancer

2012

60

First-Line PAzopanib in NOn–clear-cell Renal cArcinoMA: The Italian Retrospective Multicenter PANORAMA Study

Sebastiano Buti, Melissa Bersanelli, Francesca Maines,

Clinical Genitourinary Cancer

2016

54

Page 1